A Study of SPY003-207 in Healthy Volunteers
← catalyst calendarNCT06873724 · readout in 90 d
Sponsored by Spyre Therapeutics, Inc. (industry) · SYRE — their whole pipeline →. With Altasciences Company Inc..
Phase
Phase 1
Status
Active, not recruiting
Study type
Interventional
Design
Randomized · Quadruple · Basic science
Enrollment
59actual
Sites
2
Countries
Canada, United States
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2025-03-10 | actual | When the study began enrolling |
| Primary completion | 2026-11-18 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2026-11-18 | estimated | The whole study's end, after follow-up |
| First posted | 2025-03-13 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-03-20 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Healthy
Interventions
- Drug: SPY003-207
- Other: Placebo
Primary outcome
what the primary-completion date above is the date OFTreatment emergent adverse events
measured Up to 63 weeks
Permalink · SYRE's whole pipeline · Catalyst calendar · Every registered study · What changed